Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.

Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, Sand M, Pyke R.

J Sex Med. 2011 Nov;8(11):3160-72. doi: 10.1111/j.1743-6109.2011.02458.x. Epub 2011 Sep 20.

PMID:
21933348
2.

Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.

Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M; BEGONIA trial investigators.

J Sex Med. 2013 Jul;10(7):1807-15. doi: 10.1111/jsm.12189. Epub 2013 May 14.

PMID:
23672269
3.

Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.

Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R; VIOLET Trial Investigators.

J Sex Med. 2012 Apr;9(4):1074-85. doi: 10.1111/j.1743-6109.2011.02626.x. Epub 2012 Jan 16.

PMID:
22248038
4.

Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.

Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R; DAISY trial investigators.

J Sex Med. 2012 Mar;9(3):793-804. doi: 10.1111/j.1743-6109.2011.02595.x. Epub 2012 Jan 12.

PMID:
22239862
5.

Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial.

Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M.

Menopause. 2014 Jun;21(6):633-40. doi: 10.1097/GME.0000000000000134.

PMID:
24281236
6.

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.

Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators.

J Sex Med. 2012 Dec;9(12):3180-8. doi: 10.1111/j.1743-6109.2012.02942.x. Epub 2012 Oct 11.

PMID:
23057791
7.

Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.

Gao Z, Yang D, Yu L, Cui Y.

J Sex Med. 2015 Nov;12(11):2095-104. doi: 10.1111/jsm.13037.

PMID:
26745616
8.

Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder.

Kennedy S.

J Sex Med. 2010 Oct;7(10):3449-59. doi: 10.1111/j.1743-6109.2010.01938.x.

PMID:
20646181
9.

Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.

Dhanuka I, Simon JA.

Expert Opin Pharmacother. 2015;16(16):2523-9. doi: 10.1517/14656566.2015.1090426. Epub 2015 Sep 22. Review.

PMID:
26395164
10.

Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.

Clayton AH, Dennerstein L, Pyke R, Sand M.

Womens Health (Lond Engl). 2010 Sep;6(5):639-53. doi: 10.2217/whe.10.54. Review.

PMID:
20887163
11.

Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.

Fabre LF, Brown CS, Smith LC, Derogatis LR.

J Sex Med. 2011 May;8(5):1411-9. doi: 10.1111/j.1743-6109.2011.02216.x. Epub 2011 Feb 16.

PMID:
21324094
12.

Flibanserin for female sexual dysfunction.

Reviriego C.

Drugs Today (Barc). 2014 Aug;50(8):549-56. doi: 10.1358/dot.2014.50.8.2198036.

PMID:
25187905
13.

Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction.

Kingsberg SA, Althof SE.

J Sex Med. 2011 Dec;8(12):3262-70. doi: 10.1111/j.1743-6109.2011.02447.x. Epub 2011 Aug 24. Review.

PMID:
21883949
14.

Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.

Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET.

JAMA Intern Med. 2016 Apr 1;176(4):453-62. doi: 10.1001/jamainternmed.2015.8565.

PMID:
26927498
15.

Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.

Stahl SM, Sommer B, Allers KA.

J Sex Med. 2011 Jan;8(1):15-27. doi: 10.1111/j.1743-6109.2010.02032.x. Epub 2010 Sep 14. Review.

PMID:
20840530
16.

Chronic systemic administration of serotonergic ligands flibanserin and 8-OH-DPAT enhance HPA axis responses to restraint in female marmosets.

Aubert Y, Bohl MA, Lange JR, Diol NR, Allers KA, Sommer B, Datson NA, Abbott DH.

Psychoneuroendocrinology. 2013 Jan;38(1):145-54. doi: 10.1016/j.psyneuen.2012.05.011. Epub 2012 Jun 21.

PMID:
22727480
17.

Flibanserin: A Novel, Nonhormonal Agent for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women.

Vallejos X, Wu C.

J Pharm Pract. 2016 Feb 11. pii: 0897190016630409. [Epub ahead of print]

PMID:
26873507
18.

Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats.

Ferger B, Shimasaki M, Ceci A, Ittrich C, Allers KA, Sommer B.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381(6):573-9. doi: 10.1007/s00210-010-0515-8. Epub 2010 Apr 27.

PMID:
20422156
19.

Evaluation of the Sexual Desire Relationship Distress Scale (SDRDS) in women with hypoactive sexual desire disorder.

Revicki DA, Margolis MK, Fisher W, Rosen RC, Kuppermann M, Hanes V, Sand M.

J Sex Med. 2012 May;9(5):1344-54. doi: 10.1111/j.1743-6109.2012.02679.x. Epub 2012 Feb 29.

PMID:
22376073
20.

Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.

Stahl SM.

CNS Spectr. 2015 Feb;20(1):1-6. doi: 10.1017/S1092852914000832. Epub 2015 Feb 9. Review.

PMID:
25659981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk